NEWTOWN, Pa.--(BUSINESS WIRE)--July 20, 2006--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI - News) today announced that the U.S. Patent and Trademark Office (USPTO) has posted on its Website a nonfinal rejection of CGPI’s patent application for Oracea. On May 17, 2006, the Company announced that it had submitted additional information to the USPTO that may be relevant to the examination of U.S. Patent Application, Serial No. 10/117,709. This application relates to the use of sub-antimicrobial and non-antimicrobial tetracyclines for the treatment of acne and acne rosacea, including Oracea(TM) and incyclinide. The USPTO had previously issued a Notice of Allowance of this patent application in August 2005, and a patent was scheduled to issue on May 23, 2006. The examination to review this additional information is ongoing. In addition to this patent, there are four additional patents issued or pending covering Oracea.
